{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T06:27:54Z","timestamp":1774679274578,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ctro.2026.101113","type":"journal-article","created":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T23:19:18Z","timestamp":1769383158000},"page":"101113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["HYpofractionated, dose-redistributed RAdiotherapy (HYDRA) versus conventional radiotherapy for head and neck cancer: planned interim analysis and dosimetric comparison from the phase I HYDRA trial"],"prefix":"10.1016","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2978-2918","authenticated-orcid":false,"given":"Pascal A.","family":"Gunsch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1346-2277","authenticated-orcid":false,"given":"Michiel","family":"Kroesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reno","family":"Debets","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4665-6868","authenticated-orcid":false,"given":"Stijn","family":"Keereweer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"van Meerten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3084-4568","authenticated-orcid":false,"given":"Jaap","family":"Zindler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"van Werkhoven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4264-9903","authenticated-orcid":false,"given":"Mischa","family":"Hoogeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3513-6544","authenticated-orcid":false,"given":"Gerda M.","family":"Verduijn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Remi A.","family":"Nout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1537-4139","authenticated-orcid":false,"given":"Joris B.W.","family":"Elbers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ctro.2026.101113_b0005","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","article-title":"Head and neck squamous cell carcinoma","volume":"6","author":"Johnson","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.ctro.2026.101113_b0010","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","article-title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients","volume":"92","author":"Pignon","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2026.101113_b0015","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"issue":"10212","key":"10.1016\/j.ctro.2026.101113_b0020","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ctro.2026.101113_b0025","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S1470-2045(20)30737-3","article-title":"Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial","volume":"22","author":"Lee","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2026.101113_b0030","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.annonc.2022.10.006","article-title":"Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial","volume":"34","author":"Tao","year":"2023","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.ctro.2026.101113_b0035","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1158\/0008-5472.CAN-09-2982","article-title":"Local Radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy combined radioimmunotherapy against tumors","volume":"70","author":"Takeshima","year":"2010","journal-title":"Cancer Res"},{"issue":"20","key":"10.1016\/j.ctro.2026.101113_b0040","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1158\/1078-0432.CCR-17-3427","article-title":"Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapynodal irradiation attenuates synergy with immunotherapy","volume":"24","author":"Marciscano","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ctro.2026.101113_b0045","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3109\/07357907.2012.762780","article-title":"The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells","volume":"31","author":"Yovino","year":"2013","journal-title":"Cancer Invest"},{"issue":"1","key":"10.1016\/j.ctro.2026.101113_b0050","doi-asserted-by":"crossref","first-page":"7015","DOI":"10.1038\/s41467-022-34676-w","article-title":"Elective nodal irradiation mitigates local and systemic immunity generated by combination radiation and immunotherapy in head and neck tumors","volume":"13","author":"Darragh","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ctro.2026.101113_b0055","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s44276-024-00095-1","article-title":"The impact of elective cervical lymph node treatment on the tumour immune response in head and neck squamous cell carcinoma: time for a change in treatment strategy?","volume":"2","author":"Payne","year":"2024","journal-title":"BJC Rep"},{"issue":"4","key":"10.1016\/j.ctro.2026.101113_b0060","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.ijrobp.2021.07.1695","article-title":"The influence of severe radiation-induced lymphopenia on overall survival in solid tumors: a systematic review and meta-analysis","volume":"111","author":"Damen","year":"2021","journal-title":"Int J Radiation Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.ctro.2026.101113_b0065","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.adro.2018.08.014","article-title":"Field size effects on the risk and severity of treatment-induced lymphopenia in patients undergoing radiation therapy for solid tumors","volume":"3","author":"Ellsworth","year":"2018","journal-title":"Adv Radiat Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2026.101113_b0070","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ijrobp.2023.07.028","article-title":"Leave no cancer behind: the conformal hypofractionation era and head and neck cancer","volume":"118","author":"Lester","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.ctro.2026.101113_b0075","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.radonc.2018.04.020","article-title":"Implications of improved diagnostic imaging of small nodal metastases in head and neck cancer: radiotherapy target volume transformation and dose de-escalation","volume":"128","author":"van den Bosch","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2026.101113_b0080","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-24-02194","article-title":"Clinical benefit and safety of reduced elective dose in definitive radiotherapy for head and neck squamous cell carcinoma: the UPGRADE-RT multicenter randomized controlled trial","author":"van den Bosch","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2026.101113_b0085","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.radonc.2020.01.005","article-title":"Randomized clinical trial on reduction of radiotherapy dose to the elective neck in head and neck squamous cell carcinoma; update of the long-term tumor outcome","volume":"143","author":"Deschuymer","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2026.101113_b0090","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.radonc.2021.07.016","article-title":"Reduction of GTV to high-risk CTV radiation margin in head and neck squamous cell carcinoma significantly reduced acute and late radiation-related toxicity with comparable outcomes","volume":"162","author":"Al-Mamgani","year":"2021","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2026.101113_b0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-13-84","article-title":"Adaptive and innovative radiation treatment FOR improving cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer","volume":"13","author":"Heukelom","year":"2013","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.ctro.2026.101113_b0100","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.radonc.2018.02.015","article-title":"Dose dependence of accelerated repopulation in head and neck cancer: supporting evidence and clinical implications","volume":"127","author":"Shuryak","year":"2018","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.ctro.2026.101113_b0105","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ijrobp.2019.02.025","article-title":"Optimized hypofractionation can markedly improve tumor control and decrease late effects for head and neck cancer","volume":"104","author":"Shuryak","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2026.101113_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2020.105045","article-title":"Resource-sparing curative-intent hypofractionated-accelerated radiotherapy in head and neck cancer: more relevant than ever before in the COVID era","volume":"111","author":"Gupta","year":"2020","journal-title":"Oral Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2026.101113_b0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-018-4893-5","article-title":"Feasibility of concomitant cisplatin with hypofractionated radiotherapy for locally advanced head and neck squamous cell carcinoma","volume":"18","author":"Jacinto","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctro.2026.101113_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2020.105112","article-title":"Hypofractionated chemoradiation for head and cancer: Data from the PET NECK trial","volume":"113","author":"Vreugdenhil","year":"2021","journal-title":"Oral Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2026.101113_b0125","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1186\/s12885-023-11031-w","article-title":"HYpofractionated, dose-redistributed RAdiotherapy with protons and photons to combat radiation-induced immunosuppression in head and neck squamous cell carcinoma: study protocol of the phase I HYDRA trial","volume":"23","author":"Elbers","year":"2023","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.ctro.2026.101113_b0130","doi-asserted-by":"crossref","first-page":"354","DOI":"10.14338\/IJPT-20-00089.1","article-title":"National protocol for model-based selection for proton therapy in head and neck cancer","volume":"8","author":"Langendijk","year":"2021","journal-title":"Int J Part Ther"},{"issue":"1","key":"10.1016\/j.ctro.2026.101113_b0135","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.radonc.2013.10.010","article-title":"Delineation of the neck node levels for head and neck tumors: a 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines","volume":"110","author":"Gr\u00e9goire","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2026.101113_b0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2019.01.018","article-title":"Selection of lymph node target volumes for definitive head and neck radiation therapy: a 2019 Update","volume":"134","author":"Biau","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2026.101113_b0145","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.radonc.2019.08.005","article-title":"Practical robustness evaluation in radiotherapy - a photon and proton-proof alternative to PTV-based plan evaluation","volume":"141","author":"Korevaar","year":"2019","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.ctro.2026.101113_b0150","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ijrobp.2021.04.042","article-title":"Normal Tissue Complication Probability (NTCP) prediction model for osteoradionecrosis of the mandible in patients with head and neck cancer after radiation therapy: large-scale observational cohort","volume":"111","author":"van Dijk","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2026.101113_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109889","article-title":"Accounting for fractionation and heterogeneous dose distributions in the modelling of osteoradionecrosis in oropharyngeal carcinoma treatment","volume":"188","author":"Verduijn","year":"2023","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.ctro.2026.101113_b0160","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/0360-3016(95)00229-R","article-title":"Late normal tissue sequelae from radiation therapy for carcinoma of the tonsil: patterns of fractionation study of radiobiology","volume":"33","author":"Withers","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.ctro.2026.101113_b0165","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ijrobp.2020.06.054","article-title":"Radiation fractionation schedules published during the COVID-19 pandemic: a systematic review of the quality of evidence and recommendations for future development","volume":"108","author":"Thomson","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.ctro.2026.101113_b0170","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.ijrobp.2023.08.026","article-title":"Randomized controlled trial of hypofractionated vs. normo-fractionated accelerated radiation therapy with or without cisplatin for locally advanced head and neck squamous cell carcinoma (HYPNO)","volume":"117","author":"Bentzen","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"15","key":"10.1016\/j.ctro.2026.101113_b0175","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1002\/cncr.32968","article-title":"Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID\u201019 pandemic: the Princess Margaret experience and proposal","volume":"126","author":"Huang","year":"2020","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ctro.2026.101113_b0180","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3109\/0284186X.2014.958528","article-title":"Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma","volume":"54","author":"Thomson","year":"2015","journal-title":"Acta Oncol"},{"issue":"6","key":"10.1016\/j.ctro.2026.101113_b0185","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.clon.2018.01.015","article-title":"Feasibility of dose-escalated hypofractionated chemoradiation in human papilloma virus-negative or smoking-associated oropharyngeal cancer","volume":"30","author":"Meade","year":"2018","journal-title":"Clin Oncol"},{"issue":"8","key":"10.1016\/j.ctro.2026.101113_b0190","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/S1470-2045(23)00265-6","article-title":"Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trial","volume":"24","author":"Nutting","year":"2023","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ctro.2026.101113_b0195","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.ijrobp.2014.12.045","article-title":"Long-term quality of life after swallowing and salivary-sparing chemo\u2013intensity modulated radiation therapy in survivors of human papillomavirus\u2013related oropharyngeal cancer","volume":"91","author":"Vainshtein","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240563082600008X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240563082600008X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T04:24:48Z","timestamp":1774671888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240563082600008X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":39,"alternative-id":["S240563082600008X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2026.101113","relation":{},"ISSN":["2405-6308"],"issn-type":[{"value":"2405-6308","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HYpofractionated, dose-redistributed RAdiotherapy (HYDRA) versus conventional radiotherapy for head and neck cancer: planned interim analysis and dosimetric comparison from the phase I HYDRA trial","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2026.101113","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101113"}}